Jasper Therapeutics (JSPR) Preferred Stock Liabilities (2019 - 2021)

Jasper Therapeutics has reported Preferred Stock Liabilities for 3 years, with the latest figure at $81.3 million in Q2 2021.

• On a quarterly basis, Preferred Stock Liabilities fell 12.44% year-over-year to $81.3 million in Q2 2021; TTM through Jun 2021 was $81.3 million, a 12.44% decrease from a year earlier, with the FY2020 full-year figure at $79.4 million, down 7.55% from the prior year.
• Preferred Stock Liabilities was $81.3 million for Q2 2021 at Jasper Therapeutics, down from $84.9 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $93.1 million in Q1 2020, with the low at $79.4 million in Q4 2020.
• Average Preferred Stock Liabilities over 3 years is $87.1 million, with a median of $85.8 million recorded in 2019.
• The sharpest annual moves came in 2020 and 2021: Preferred Stock Liabilities retreated 7.55% in 2020, then slipped 12.44% in 2021.
• Over 3 years, Preferred Stock Liabilities stood at $85.8 million in 2019, then declined by 7.55% to $79.4 million in 2020, then gained by 2.43% to $81.3 million in 2021.
• The last three Preferred Stock Liabilities figures came in at $81.3 million (Q2 2021), $84.9 million (Q1 2021), and $79.4 million (Q4 2020), per Business Quant data.